Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 257

1.

Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results.

Mishkel GJ, Moore AL, Markwell SJ, Ligon RW.

J Invasive Cardiol. 2007 Feb;19(2):63-8.

PMID:
17268039
[PubMed - indexed for MEDLINE]
2.

Bivalirudin and DES: a PCI strategy that pays.

Applegate RJ.

J Invasive Cardiol. 2007 Feb;19(2):69-70. No abstract available.

PMID:
17268040
[PubMed - indexed for MEDLINE]
3.

Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.

Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ.

J Am Coll Cardiol. 2004 Nov 2;44(9):1792-800.

PMID:
15519009
[PubMed - indexed for MEDLINE]
Free Article
4.

Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.

Feldman DN, Wong SC, Bergman G, Minutello RM.

J Invasive Cardiol. 2009 Jun;21(6):258-63.

PMID:
19494400
[PubMed - indexed for MEDLINE]
Free Article
5.

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.

PMID:
12588269
[PubMed - indexed for MEDLINE]
6.

Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.

Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.

Am Heart J. 2007 Oct;154(4):695-701. Epub 2007 Aug 20.

PMID:
17892994
[PubMed - indexed for MEDLINE]
7.

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.

Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators.

JAMA. 2004 Aug 11;292(6):696-703. Erratum in: JAMA. 2006 Jul 5;296(1):46.

PMID:
15304466
[PubMed - indexed for MEDLINE]
8.

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.

Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.

Am Heart J. 2006 Jul;152(1):149-54.

PMID:
16824845
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.

Kim LK, Wong SC, Minutello RM, Bergman G, Feldman DN.

J Invasive Cardiol. 2010 Mar;22(3):94-100.

PMID:
20197573
[PubMed - indexed for MEDLINE]
Free Article
10.

Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.

Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, Mehran R, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ; ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators.

J Am Coll Cardiol. 2008 Nov 25;52(22):1758-68. doi: 10.1016/j.jacc.2008.08.021.

PMID:
19022155
[PubMed - indexed for MEDLINE]
Free Article
11.

Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.

Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ; REPLACE-2 Investigators.

J Am Coll Cardiol. 2004 Sep 15;44(6):1194-9.

PMID:
15364319
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.

Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators.

Lancet. 2007 Mar 17;369(9565):907-19.

PMID:
17368152
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.

Schwenkglenks M, Brazier JE, Szucs TD, Fox KA.

Value Health. 2011 Jan;14(1):24-33. doi: 10.1016/j.jval.2010.10.025.

PMID:
21211483
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.

Summers KM, Holdford DA, Crouch MA.

Pharmacotherapy. 2006 May;26(5):609-18.

PMID:
16637790
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction.

Schwenkglenks M, Toward TJ, Plent S, Szucs TD, Blackman DJ, Baumbach A.

Heart. 2012 Apr;98(7):544-51. doi: 10.1136/heartjnl-2011-301323. Epub 2012 Feb 7.

PMID:
22313548
[PubMed - indexed for MEDLINE]
17.

Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.

Showkathali R, Davies JR, Parker M, Taggu W, Tang KH, Clesham GJ, Gamma RA, Sayer JW, Aggarwal RK, Kelly PA.

Cardiovasc Revasc Med. 2013 Sep-Oct;14(5):289-93. doi: 10.1016/j.carrev.2013.07.006. Epub 2013 Aug 22.

PMID:
23972537
[PubMed - indexed for MEDLINE]
18.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

PMID:
18499566
[PubMed - indexed for MEDLINE]
Free Article
20.

Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.

Wöhrle J, Merkle N, Kunze M, Cristea E, Mehran R, Rottbauer W, Stone GW.

Catheter Cardiovasc Interv. 2012 Jun 1;79(7):1083-9. doi: 10.1002/ccd.23179. Epub 2011 Dec 7.

PMID:
22162175
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk